Go or no go? Ardelyx and Chemocentryx among those waiting FDA decisions
Big regulatory events for July include a panel for Fibrogen's roxadustat and decision time for Albireo; elsewhere, Jak inhibitor delays could persist.
AASLD 2020 – Nash updates from Novo and Inventiva in focus
At the US liver conference Inventiva will make a case for PPAR agonism, while Novo Nordisk and Gilead’s combo will be scrutinised in Nash.
Albireo sets the standard for Mirum to hit
Mirum has it all to do after Albireo gets a result with lead project odevixibat in a rare childhood liver disease.
Big pharma spinouts grow up
Companies formed around unwanted big pharma assets have a mixed record, although some parents are better at finding spinouts than others.
Rare diseases dominate catalysts for the smallest companies
Our final look at third-quarter events focuses this time on the smallest players, with data from Amryt, Ovid, Bellus and more.
EASL 2019 preview – Viking and Spring Bank abstracts pique early interest
High-profile presentations from the likes of Intercept and Alnylam remain under wraps before Europe’s biggest liver disease conference next month, but the early abstract…
Albireo comes up to IBAT in Nash
Albireo is taking aim at yet another Nash target, but Shire and Glaxosmithkline have already ditched projects with similar mechanisms.
